Home » Agenda » Day 2

Day 2

3rd Real-World Evidence World Congress 2025 Europe

Hilton London Kensington, London, UK

Day 2 - Wednesday 30th April 2025

CHALLENGES AND POTENTIALS

  • Challenges that could inhibit the administration and efficiency of RWE
  • Best practices and lessons learned from other industries
  • Collaboration between regulators and RWD/RWE organisations to develop collective experience so that RWE use can be better regulated
  • Analyzing RWD to determine brand marketing effectiveness
  • Major factors contributing to the pharmaceutical industry’s excitement about RWE
  • Addressing the challenges of collecting and consolidating RWD data that can be put to good use.
  • Important role of RWE clinical trials
  • Real-world data and evidence as a more integral part of the drug development process.

 

  • How are patient registries used to generate real-world data for rare diseases and orphan drugs?
  • Does different stakeholder types have different RWE information needs for decision making?
  • Well-targeted evidence which encourages orphan medicine adoption by supporting the approval, reimbursement, and prescribing
  • Benefits of understanding differences across stakeholders
  • Multiple stakeholder approach to planning and delivering evidence is required
  • A dedicated strategy to meet their specific evidence needs
  • Determine whether a multiple stakeholder approach is justified.
  • The shift from RCT to RWE; closing the gap
  • Best practices and lessons learned in developing robust RWE studies
  • Using Real-World Evidence to accelerate market access
  • Example of technologies currently being used to harness data
  • Are there pitfalls in using these technologies?
  • How are these new technologies providing valuable understanding of the use of RWE in real-world settings
  • Upcoming development
  • Collection of high-quality patient-centered data relevant to the design, conduct, and translation of real- world research.
  • Applying qualitative patient experience data to make informed study design decisions
  • Recommendations that may improve the patient centricity of RWE
  • Why personalised medicines require RWE and disruptive technologies intervention?
  • Data that have potential to be implemented in personalized medicines discovery
  • How will RWE curve the future path of personalized, precision medicines
  • Glimpse into a future of next-generation medicine
  • Recent advances in scientific research and technologies
  • Main areas that need improvement
  • Innovative strategies needed to engage patients and generate the necessary evidence to propel new advances into the clinic
  • Latest changes in RWE landscape and its advantages
  • What exciting new breakthroughs exist for RWE?
  • The next big innovations and advances in RWE
  • Perspective on future directions and harmonisation
Scroll to Top